Plasma is becoming an increasingly popular biological sample to identify diagnostic biomarkers as its protein composition uniquely reflects the body’s physiological state. Recent studies have demonstrated that using MS-based plasma proteomics not only enables the identification of biomarkers but also potential therapeutic targets.
To enhance plasma proteomics research, Biognosys developed the PQ500 Reference Peptides kit. The kit contains an optimized set of 804 SIS peptides that target 582 plasma proteins. The use of heavy labeled reference peptides provides numerous benefits, especially for large-scale plasma analyses that involve large sample cohorts.
In this seminar, Biognosys’ Principal Scientist Sebastian Müller dives into how the use of PQ500 helps overcome typical limitations in large-scale projects, such as repeatability and consistency of results. In addition, PQ500 combined with SureQuant acquisition provides exceptional analytical depth and unmatched quantitative accuracy.
Manuel Mayr, Professor of Cardiovascular Proteomics at King’s College London, highlights the above-mentioned benefits during the presentation of his work using PQ500 in DIA mode and Biognosys’ software Spectronaut to identify biomarkers that predict mortality in COVID-19 patients.
The seminar concluded with a Q&A session chaired by Biognosys’ Fabia Simona.
Access our knowledge base with relevant resources and guiding information.